CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

CASI Pharmaceuticals, Inc.

Zenith Services provides a suite of IT solutions, including digital transformation, healthcare staffing, cyber security, software development, nearshoring, and artificial intelligence services, serving businesses to enhance their technological capabilities.

Zenith Services

CASI Pharmaceuticals is an innovative biopharmaceutical company developing an anti-CD38 monoclonal antibody treatment for organ transplant rejection and autoimmune diseases. self-described.

CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. | 1,104 followers on LinkedIn. Bringing life-changing therapeutics to China and the world. | CASI is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China through which all of our China operations are conducted.

Metric
Company Name	CASI Pharmaceuticals, Inc.	Zenith Services
Symbol	CASI
MSH ID	COM:CASIPHARMACEUTICALS	COM:ZENITHCAD
Market	STOCKS	PRIVATE
Sector	Healthcare	Technology
Industry	Biotechnology	Information Technology
Country	US	US
Stage
Employee Count	176
Website	casipharmaceuticals.com	zenithcad.com
LinkedIn	casi-pharmaceuticals-inc.	zenith-services-inc
Founders

Metric
Market Cap	87.38M
Enterprise Value
Monthly Web Traffic	2.21K	473
Web Traffic Growth	0.80	2.31
Valuation
Raised Capital	15M

Metric
Revenue	33.88M
Revenue (LTM)
Revenue (NTM)
Gross Profit	18.98M
EBITDA	-27.91M
Operating Income	-31.65M
Net Income	-26.94M
EPS	-2.02
Diluted EPS	-2.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.64
Operating Profit Margin	-0.24
EBITDA Margin	-0.82
Net Profit Margin	-0.80
Return on Equity	-0.84
Return on Assets	-0.35
Return on Capital Employed	-0.16

COM:CASIPHARMACEUTICALS

CASI Pharmaceuticals

Last Close

5.29

22/11 21:00

Market Cap

87.38M

Beta: -

Volume Today

16.02K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-2.08
P/B Ratio	2.84
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.51
EV Multiple	-1.30

Metric
Days Sales Outstanding	100.66
Days Payables Outstanding	61.21
Days Inventory Outstanding	565.35
Operating Cycle	692.01
Cash Conversion Cycle	661.37
Asset Turnover	0.57

Metric
Operating Cash Flow	-19.97M
Free Cash Flow	-22.21M
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield	-0.14

Metric
Cash & Equivalents	17.08M
Accounts Receivable	2.83M
Inventory	15.88M
Goodwill
Debt to Capitalization	0.63
Debt to Assets
Current Ratio	4.91
Quick Ratio	4.00

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.08
R&D to Revenue	0.28
SG&A to Revenue	0.63